Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283520623> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- W4283520623 endingPage "S413" @default.
- W4283520623 startingPage "S413" @default.
- W4283520623 abstract "Fampridine is the only approved symptomatic drug to improve multiple sclerosis (MS) related walking disability globally. This study aims to evaluate the cost-effectiveness of adding fampridine to best supportive care (BSC) versus BSC alone for the improvement of walking ability in adult MS patients with Expanded Disability Status Scale (EDSS) score 4-7 in China. A cost-utility analysis was conducted based on a hybrid decision tree and Markov model from both the societal and healthcare system perspective in China. The modelled treatment effect and utility data were derived from the phase III trial (ENHANCE) of fampridine. The BSC was consisted of other supportive drugs, outpatient visits, examination and lab tests, hospitalization and rehabilitation. The fampridine plus BSC strategy considered the drug cost and adverse event management cost of fampridine additionally. Costs of walking aids and productivity loss were also included in the societal perspective. Unit costs and utilization of healthcare resource were obtained from published source or physicians’ interview. Both quality-adjusted life years (QALY) and costs were discounted at a rate of 5%, and a half-cycle correction was applied. Uncertainty was assessed by one-way and probabilistic sensitivity analyses. Over a 10-year time horizon, adding fampridine to BSC led to an incremental QALY gain of 0.15 and lower total costs from both perspectives. The addition of fampridine reduced the cost of healthcare resource use, especially costs of rehabilitation, other supportive drugs and outpatient visits. In addition, fampridine plus BSC strategy presented lower costs of walking aids and productivity loss of patients & caregivers from the societal perspective. Sensitivity analyses confirmed the robustness of the results. Compared to BSC alone, fampridine plus BSC is considered as an economically dominant strategy (better effectiveness and lower costs) for adult patients with MS with EDSS 4-7 in China." @default.
- W4283520623 created "2022-06-27" @default.
- W4283520623 creator A5030091211 @default.
- W4283520623 creator A5032291919 @default.
- W4283520623 creator A5038583580 @default.
- W4283520623 creator A5051341979 @default.
- W4283520623 creator A5061386164 @default.
- W4283520623 date "2022-07-01" @default.
- W4283520623 modified "2023-09-29" @default.
- W4283520623 title "EE400 Cost-Effectiveness Analysis of Fampridine for Multiple Sclerosis Treatment in China" @default.
- W4283520623 doi "https://doi.org/10.1016/j.jval.2022.04.648" @default.
- W4283520623 hasPublicationYear "2022" @default.
- W4283520623 type Work @default.
- W4283520623 citedByCount "0" @default.
- W4283520623 crossrefType "journal-article" @default.
- W4283520623 hasAuthorship W4283520623A5030091211 @default.
- W4283520623 hasAuthorship W4283520623A5032291919 @default.
- W4283520623 hasAuthorship W4283520623A5038583580 @default.
- W4283520623 hasAuthorship W4283520623A5051341979 @default.
- W4283520623 hasAuthorship W4283520623A5061386164 @default.
- W4283520623 hasBestOaLocation W42835206231 @default.
- W4283520623 hasConcept C1862650 @default.
- W4283520623 hasConcept C71924100 @default.
- W4283520623 hasConcept C99508421 @default.
- W4283520623 hasConceptScore W4283520623C1862650 @default.
- W4283520623 hasConceptScore W4283520623C71924100 @default.
- W4283520623 hasConceptScore W4283520623C99508421 @default.
- W4283520623 hasIssue "7" @default.
- W4283520623 hasLocation W42835206231 @default.
- W4283520623 hasOpenAccess W4283520623 @default.
- W4283520623 hasPrimaryLocation W42835206231 @default.
- W4283520623 hasRelatedWork W1821496887 @default.
- W4283520623 hasRelatedWork W2021242201 @default.
- W4283520623 hasRelatedWork W2092185945 @default.
- W4283520623 hasRelatedWork W2103412063 @default.
- W4283520623 hasRelatedWork W2742678697 @default.
- W4283520623 hasRelatedWork W2913230942 @default.
- W4283520623 hasRelatedWork W3189279688 @default.
- W4283520623 hasRelatedWork W4224285088 @default.
- W4283520623 hasRelatedWork W4293168876 @default.
- W4283520623 hasRelatedWork W4362694235 @default.
- W4283520623 hasVolume "25" @default.
- W4283520623 isParatext "false" @default.
- W4283520623 isRetracted "false" @default.
- W4283520623 workType "article" @default.